ARS Pharmaceuticals, Inc. Restructuring Charges
ARS Pharmaceuticals, Inc. (SPRY) reported Restructuring Charges of $2.00 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Operating Expenses
us-gaap:RestructuringCharges · last filed 2022-08-11
- ARS Pharmaceuticals, Inc. restructuring charges for the quarter ending 2022-06-30 was $0.00.
- ARS Pharmaceuticals, Inc. restructuring charges for the quarter ending 2022-03-31 was $2.00M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month |
|---|---|---|
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.00M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $2.00M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |